查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1588573

全球綜合器官支持療法市場 - 2024-2031

Global Integrated Organ Support Therapies Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球綜合器官支持療法市場在2023年達到39.1億美元，預計到2031年將達到59.6億美元，在2024-2031年預測期間複合年成長率為5.5%。

綜合器官支持療法是一套多學科、協調一致的醫療干預措施和設備，旨在維持、支持或暫時替代危重患者一個或多個衰竭器官的功能。這些療法主要用於重症監護室和急診護理機構，這些機構中的患者患有嚴重的健康狀況，包括多重器官衰竭、敗血症、呼吸窘迫、急性腎損傷或肝衰竭等。

綜合器官支持療法旨在維持器官功能，以防止不可逆轉的損傷並穩定患者的病情，同時治療根本原因或使身體痊癒。例如，根據organdonor.gov的數據，全國移植等待名單上有103,223名男性、女性和兒童，在這種情況下，這些綜合器官支持療法可能會有所幫助，這進一步有助於推動市場成長。

市場動態：

司機

慢性和急性器官衰竭的盛行率上升

慢性和急性器官衰竭的盛行率不斷上升，與對能夠同時管理或替代多個器官功能的綜合器官支持療法的需求不斷成長直接相關，因為這些情況顯著增加了對生命支持干預措施和多器官管理的需求。慢性和急性器官衰竭都會損害身體執行基本功能的能力，因此需要整合的器官支持設備和療法來暫時替代或支持這些衰竭的器官。

例如，根據美國國立衛生研究院 (NIH) 進行的研究，該研究顯示新器官衰竭的發生率為 1,342/1,00,000 人年，在所有急診接觸者中的盛行率為 5.2%。器官衰竭患者的一年全因死亡率為 29.8%。隨著器官衰竭的增加，對綜合器官支持療法的需求預計將持續成長。

限制

與器官支持療法和設備相關的風險和併發症、器官支持設備和療法的高成本、複雜的法規核准流程、高維護和操作要求以及設備的便攜性和移動性有限等因素預計將阻礙綜合器官支持療法市場。

雖然這些療法對於治療多重器官衰竭患者至關重要，但相關的風險、併發症和潛在副作用可能會影響其採用和療效。使用此類設備的複雜性也給醫療保健系統帶來了額外的負擔，這可能會阻礙市場的成長。

例如，與器官支持療法相關的最嚴重的併發症之一是感染風險增加，尤其是體外膜氧合（ECMO）和連續腎臟替代療法（CRRT）等侵入性設備。許多器官支持裝置，特別是 ECMO 和 CRRT，涉及體外循環血液，這進一步帶來了血栓形成或出血的重大風險。這些風險可能會阻礙市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 慢性和急性器官衰竭的盛行率上升
      • 器官支持裝置的技術進步
    • 限制
      • 與器官支持療法和設備相關的風險和併發症
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT分析
  • 未滿足的需求

第 6 章：按治療類型

  • 體外膜氧合（ECMO）
    • 靜脈-靜脈 (VV)
    • 靜脈-動脈 (VA)
    • 動靜脈 (AV)
  • 連續性腎臟替代療法（CRRT）
    • 連續性靜脈靜脈血液濾過（CVVH）
    • 連續性靜脈-靜脈血液透析（CVVHD）
    • 連續性靜脈靜脈血液透析濾過（CVVHDF）
    • 慢速連續超濾 (SCUF)
  • 體外二氧化碳去除 (ECCO2R)
  • 肝臟支援系統
    • 分子吸附劑循環系統
    • 生物人工肝支持
  • 心臟輔助裝置
    • 主動脈內球囊反搏器
    • 心室輔助裝置
    • 人工器官總數

第 7 章：按形態

  • 攜帶式/攜帶式設備
  • 床邊設備
  • 植入式裝置

第 8 章：按申請

  • 呼吸衰竭
  • 心臟衰竭
  • 肝衰竭
  • 腎衰竭
  • 多重器官衰竭

第 9 章：依病患類型

  • 成人患者
  • 兒科患者
  • 新生兒患者

第 10 章：最終用戶

  • 醫院
  • 專科診所
  • 門診手術中心
  • 加護病房 (ICU)

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • Emulate, Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Baxter International Inc.
  • Fresenius Medical Care AG
  • Getinge AB
  • LivaNova, Inc.
  • Asahi Kasei Corporation
  • ADVITOS GmbH
  • NIHON KOHDEN CORPORATION
  • Vapotherm
  • Fisher & Paykel Healthcare Limited

第 14 章：附錄

簡介目錄
Product Code: OT8718

Overview

The global integrated organ support therapies market reached US$ 3.91 billion in 2023 and is expected to reach US$ 5.96 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.

Integrated organ support therapies are a multidisciplinary and coordinated set of medical interventions and devices that are designed to sustain, support or temporarily replace the functions of one or multiple failing organs in critically ill patients. These therapies are primarily used in intensive care units and acute care settings where patients suffer from severe health conditions, including multi-organ failure, sepsis, respiratory distress, acute kidney injury or liver failure and among others.

Integrated organ support therapies aim to maintain organ functions to prevent irreversible damage and stabilize patients while underlying causes are treated or the body heals. For instance, according to organdonor.gov, 103,223 men, women and children are on the national transplant waiting list, in such cases, these integrated organ support therapies may be helpful, which further helps to boost the market growth.

Market Dynamics: Drivers

Rising prevalence of chronic and acute organ failures

The increasing prevalence of both chronic and acute organ failures directly correlates with the rising demand for integrated organ support therapies that can manage or replace the function of multiple organs simultaneously, as these conditions significantly increase the need for life-support interventions and multi-organ management. Both chronic and acute organ failures impair the body's ability to perform essential functions, necessitating integrated organ support devices and therapies that can temporarily replace or support these failing organs.

For instance, according to the study conducted by the National Institute of Health (NIH), the study revealed the incidence of new organ failure at 1,342/1,00,000 person-years and a prevalence of 5.2% of all emergency department contacts. One-year all-cause mortality was 29.8% among organ failure patients. As organ failures are on the rise, the demand for integrated organ support therapies is expected to grow continuously.

Restraints

Factors such as risks and complications associated with organ support therapies and devices, high costs of organ support devices and therapies, complex regulatory approval processes, high maintenance and operational requirements and limited portability and mobility of devices are expected to hamper the integrated organ support therapies market.

While these therapies are essential for managing patients with multi-organ failure, the associated risks, complications and potential side effects can affect their adoption and efficacy. The complexity of using such devices also places an additional burden on healthcare systems, which can hamper the growth of the market.

For instance, one of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, this further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.

Segment Analysis

The global integrated organ support therapies market is segmented based on therapy type, modality, application, patient type, end-user and region.

The multi-organ failure from the application segment accounted for approximately XX% of the global integrated organ support therapies market share

The multi-organ failure segment is expected to hold the largest market share over the forecast period. Integrated organ support therapies are critical in the management of multi-organ failure, a condition where two or more organs fail simultaneously, often resulting from severe infections, trauma or underlying chronic conditions. These therapies provide life-sustaining support to failing organs, enabling doctors to stabilize the patient while the underlying causes are treated or recovery occurs.

For instance, according to a study conducted by ScienceDirect, in surgical critical care units, 50-80% of all deaths are due to multiple organ failure (MOF). The origin of MOF is still not well understood, therapy is still mainly supportive and the death rate (30-70% in most series) has not significantly decreased even though the syndrome was first identified more than 20 years ago. Thus, the rising burden of MOF further increases the demand for integrated organ support therapies.

Geographical Analysis

North America accounted for approximately XX% of the global integrated organ support therapies market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases and critical illnesses and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.

For instance, according to the American Kidney Fund Organization, about 808,000 Americans are living with kidney failure. According to the CDC, the US Department of Health and Human Services estimated that 129 million Americans suffer from at least one severe chronic disease.

The U.S. healthcare system is the largest spender on healthcare globally. For instance, according to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's GDP, health spending accounted for 17.3%, which includes significant expenditures on critical care technologies, including ECMO, CRRT and others.

Market Segmentation

By Therapy Type

  • Extracorporeal Membrane Oxygenation (ECMO)
    • Veno-Venous (VV)
    • Veno-Arterial (VA)
    • Arterio-Venous (AV)
  • Continuous Renal Replacement Therapy (CRRT)
    • Continuous Venovenous Hemofiltration (CVVH)
    • Continuous Venovenous Hemodialysis (CVVHD)
    • Continuous Venovenous Hemodiafiltration (CVVHDF)
    • Slow Continuous Ultrafiltration (SCUF)
  • Extracorporeal CO2 Removal (ECCO2R)
  • Liver Support Systems
    • Molecular Adsorbent Recirculating System
    • Bioartificial Liver Support
  • Cardiac Assist Devices
    • Intra-aortic Balloon Pump
    • Ventricular Assist Devices
    • Total Artificial Organs

By Modality

  • Portable/Transportable Devices
  • Bedside Devices
  • Implantable Devices

By Application

  • Respiratory Failure
  • Cardiac Failure
  • Liver Failure
  • Kidney Failure
  • Multi-Organ Failure

By Patient Type

  • Adult Patients
  • Pediatric Patients
  • Neonatal Patients

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Intensive Care Units (ICUs)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the integrated organ support therapies market include Emulate, Inc., Baxter International Inc., Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, Fisher & Paykel Healthcare Limited and among others.

Key Developments

  • In August 2024, Talphera, Inc. declared that the NEPHRO CRRT study's first patient has been recruited. 166 individuals receiving continuous renal replacement therapy (CRRT) at up to 14 clinical locations across the US will be included in the NEPHRO CRRT registrational research. The mean post-filter activated clotting time for circuits injected with nafamostat versus placebo for the first 24 hours is the study's main outcome.
  • In April 2022, Baxter International Inc. released the U.S. Food and Drug Administration (FDA) 510(k) clearance 0f ST Set for use in continuous renal replacement therapy (CRRT). The ST Set is a disposable, extracorporeal (outside the body) circuit that comes pre-connected and may be used with the PrisMax or Prismaflex control units (monitors). It purifies blood through a semipermeable membrane.

Why Purchase the Report?

  • To visualize the global integrated organ support therapies market segmentation based on therapy type, modality, application, patient type, end-user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the integrated organ support therapies market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global integrated organ support therapies market report would provide approximately 78 tables, 77 figures and 179 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Modality
  • 3.3. Snippet by Application
  • 3.4. Snippet by Patient Type
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic and Acute Organ Failure
      • 4.1.1.2. Technological Advancements in Organ Support Devices
    • 4.1.2. Restraints
      • 4.1.2.1. Risks and Complications Associated with Organ Support Therapies and Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Therapy Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 6.1.2. Market Attractiveness Index, By Therapy Type
  • 6.2. Extracorporeal Membrane Oxygenation (ECMO)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Veno-Venous (VV)
    • 6.2.4. Veno-Arterial (VA)
    • 6.2.5. Arterio-Venous (AV)
  • 6.3. Continuous Renal Replacement Therapy (CRRT)
    • 6.3.1. Continuous Venovenous Hemofiltration (CVVH)
    • 6.3.2. Continuous Venovenous Hemodialysis (CVVHD)
    • 6.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
    • 6.3.4. Slow Continuous Ultrafiltration (SCUF)
  • 6.4. Extracorporeal CO2 Removal (ECCO2R)
  • 6.5. Liver Support Systems
    • 6.5.1. Molecular Adsorbent Recirculating System
    • 6.5.2. Bioartificial Liver Support
  • 6.6. Cardiac Assist Devices
    • 6.6.1. Intra-aortic Balloon Pump
    • 6.6.2. Ventricular Assist Devices
    • 6.6.3. Total Artificial Organs

7. By Modality

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 7.1.2. Market Attractiveness Index, By Modality
  • 7.2. Portable/Transportable Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bedside Devices
  • 7.4. Implantable Devices

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Respiratory Failure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Failure
  • 8.4. Liver Failure
  • 8.5. Kidney Failure
  • 8.6. Multi-Organ Failure

9. By Patient Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 9.1.2. Market Attractiveness Index, By Patient Type
  • 9.2. Adult Patients*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Pediatric Patients
  • 9.4. Neonatal Patients

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Intensive Care Units (ICUs)

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Emulate, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Baxter International Inc.
  • 13.3. Fresenius Medical Care AG
  • 13.4. Getinge AB
  • 13.5. LivaNova, Inc.
  • 13.6. Asahi Kasei Corporation
  • 13.7. ADVITOS GmbH
  • 13.8. NIHON KOHDEN CORPORATION
  • 13.9. Vapotherm
  • 13.10. Fisher & Paykel Healthcare Limited

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us